Immatics Eyes 2027 Melanoma Drug Launch, Fueled by Strategic Investment

HOUSTON, TX & TUEBINGEN, GERMANY – March 05, 2026 – Immatics N.V. has outlined a clear path toward commercializing its lead cancer therapy, projecting a 2027 market launch while posting a strategic net loss for 2025 driven by a significant ramp-up in research and development. In its full-year financial results and business update, the biopharmaceutical company showcased major clinical progress across its oncology franchise, which targets the widespread cancer protein PRAME, and reassured investors with a strong financial position and a cash runway extending into 2028.

The company’s lead candidate, the cell therapy anzu-cel, is advancing through a pivotal Phase 3 trial for advanced melanoma, headlining what is expected to be a year of high-impact clinical milestones.

“Following a year of strong execution and data updates across our entire PRAME franchise, Immatics is entering 2026 with multiple high-impact milestones ahead, including advancing our PRAME cell therapy, anzu-cel, towards approval,” said Harpreet Singh, Ph.D., Chief Executive Officer and Co-Founder of Immatics. “Above all, we remain focused on translating this positive momentum into transformative outcomes for patients with cancer.”

Balancing Ambition with the Bottom Line

Immatics reported a net loss of $230.8 million (€196.4 million) for 2025, a stark contrast to the net profit of $17.9 million (€15.2 million) recorded in 2024. However, this financial shift is not indicative of operational distress but rather a calculated strategy of aggressive investment. The 2024 profit was largely influenced by a one-time, non-cash revenue recognition event following the termination of a collaboration with Bristol Myers Squibb.

Conversely, the 2025 loss was primarily fueled by a surge in R&D expenses, which climbed to $216.0 million from $174.0 million in the prior year. This increased spending directly supports the advancement of its clinical pipeline, most notably the global Phase 3 trial for anzu-cel.

Despite the reported loss, the company’s financial health remains robust. Immatics ended 2025 with $551.4 million in cash and other financial assets, bolstered by a $125 million public offering in December. This substantial capital reserve is projected to fund operations into 2028, a healthy runway that positions it favorably within the biotech sector. The financial strategy has earned confidence from market analysts, who maintain a “Strong Buy” consensus rating on the company, seeing the current spending as a necessary investment to unlock the long-term value of its innovative cancer therapies.

Anzu-cel: The Vanguard in a New Wave of Melanoma Treatment

The centerpiece of Immatics’ strategy is anzu-cel, a T-cell therapy engineered to target PRAME. The ongoing global, randomized, controlled Phase 3 SUPRAME trial is evaluating the therapy in patients with advanced cutaneous melanoma who have already been treated with checkpoint inhibitors. The company reaffirmed its timelines, expecting key data analyses in 2026, a Biologics License Application (BLA) submission to the FDA in the first half of 2027, and a potential commercial launch in the second half of 2027.

Anzu-cel’s path to market is bolstered by significant regulatory support. The FDA has granted it both Orphan Drug Designation and Regenerative Medicine Advanced Therapy (RMAT) designation for cutaneous and uveal melanoma. These designations are reserved for promising therapies addressing serious, unmet medical needs and can expedite the development and review process.

For an estimated 9,000 patients annually in the U.S. and Europe with advanced melanoma, anzu-cel represents a new potential option. While the treatment landscape includes powerful checkpoint inhibitors like Keytruda and other cell therapies like Amtagvi, many patients eventually stop responding or are not eligible for these treatments. By precisely targeting PRAME, a protein highly expressed in melanoma and other cancers but rare in healthy tissue, anzu-cel offers a novel mechanism of action that could provide durable responses where other therapies have failed.

Beyond Melanoma: Building a PRAME Powerhouse

Immatics' ambition extends far beyond a single drug or indication. The company is leveraging its expertise to build the industry’s broadest PRAME-focused franchise, attacking the target with multiple technologies across a wide array of cancers.

Key pipeline developments include:

• IMA203CD8: A second-generation PRAME cell therapy designed for enhanced potency. A data update from its Phase 1a trial, with a focus on patients with ovarian cancer, is planned for the first half of 2026. Early results have shown promising anti-tumor activity and could position this candidate for a tumor-agnostic development path.

• IMA402: An “off-the-shelf” TCR bispecific, a different type of immunotherapy that doesn't require patient-specific cell manufacturing. Immatics plans to report expanded clinical data in the second half of 2026, focusing on melanoma and gynecologic cancers, and may initiate registration-enabling trials based on the results.

• Combination Therapies: Looking for synergistic effects, Immatics will initiate a trial in 2026 combining IMA402 with another bispecific, IMA401 (targeting MAGEA4/8), for patients with squamous non-small cell lung cancer (sqNSCLC). This strategy of combining different targeted immunotherapies could create more powerful anti-cancer effects.

The mRNA Frontier: A Deepened Moderna Alliance

Further cementing its position at the cutting edge of immunotherapy is an expanded collaboration with mRNA giant Moderna. The partnership is exploring a novel approach by combining anzu-cel with an mRNA-based PRAME “enhancer,” with the first patient dosed in a Phase 1 trial in late 2025.

More significantly, the collaboration is advancing the first mRNA-based TCER® (T-Cell Engaging Receptor) into clinical development. This groundbreaking technology uses mRNA to instruct a patient's own body to produce the cancer-fighting bispecific molecules in vivo. Immatics will conduct the Phase 1 trial, fully funded by Moderna. Success in this area could pioneer a new class of readily available, potent immunotherapies, validating a “multiplexing” strategy that could be applied across numerous cancers.

As Immatics barrels toward these clinical and regulatory milestones, it is also building its corporate infrastructure. The recent appointments of Venkat Ramanan, Ph.D., as Chief Financial Officer and Amie Krause as Chief People Officer signal a company preparing for the complexities of commercialization and scaling its operations. This strategic build-out underscores a clear transition from a purely clinical-stage entity to one on the cusp of delivering its therapies directly to patients.